Reuters logo
UPDATE 1-ZymoGenetics' skin cancer drug shows promise in study
September 29, 2010 / 11:56 AM / 7 years ago

UPDATE 1-ZymoGenetics' skin cancer drug shows promise in study

* Overall survival at 12.4 months

* 53 pct patients survive at 12 months

* Shares up 4 pct premarket

Sept 29 (Reuters) - ZymoGenetics Inc ZGEN.O said its experimental skin cancer drug showed promising survival data in a mid-stage trial, sending the biotechnology firm’s shares up 4 percent.

The study, conducted with recombinant Interleukin 21 (IL-21) as a single agent, showed overall survival of 12.4 months, the company said in a statement.

Zymogenetics said 53 percent of the total 40 patients enrolled in the study survived at 12 months.

Shares of the Seattle-based firm touched a 52-week high of $9.79 on Sept. 8 after Bristol-Myers Squibb Co (BMY.N) said it would acquire ZymoGenetics in a deal valued at $885 million. [ID:nN07253834]

They were trading up 4 percent at $10.15 in premarket trading Wednesday. The stock closed at $9.75 Tuesday on Nasdaq. (Reporting by Rajarshi Basu in Bangalore; Editing by Maju Samuel)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below